I was hoping that the short term chart would provide another chance to fill out my position in the 20's. It did. I expect that the short term pattern may soon be eclipsed by the longer term upward chart pattern. Hopefully tomorrows cc provides the impetus for this move.
I started listing out the growth drivers for GHDX and got to 10 and decided it was a screaming buy.
My father died more than a decade ago from prostate cancer, and I believe that that the OncoType DX test has the potential to be a real game changer in men's health.
I agree.. Shares being stolen today. I think numbers will be decent tomorrow and will keep getting better. I have 1 last order in 28s if they wanna fill it today. Solid company. Solid growth. Undervalued.
I see tomorrows report as providing another data point. Likely to see continued strong rev growth but earnings will be depressed and reflect the costs of launching the prostate test. Real growth in earnings will be apparent when the Urology sales force is fully staffed and the payer codes (medicare etc.) are in place for the prostate test. That could be a year away.